Zealand Petrelintide Hits Double Digit Weight Loss In Phase Two

With a global Phase 3 registrational program already initiated, Zealand Pharma's petrelintide is moving into large-scale clinical manufacturing territory, and the ZUPREME-1 Phase 2 data published in The Lancet Diabetes & Endocrinology set the efficacy and tolerability benchmarks that will anchor those trials. For process development and QA teams now scoping once-weekly subcutaneous peptide injectable platforms, the dataset offers a clearer picture of the dose range and formulation parameters that will need to be locked down ahead of Phase 3 process validation.

ZUPREME-1 was a randomized, double-blind, placebo-controlled, dose-finding study enrolling 485 adults across 32 sites in the United States, Poland, and Romania. Participants received once-weekly subcutaneous injections of petrelintide at five dose levels, 1.0 mg, 2.5 mg, 5.0 mg, 7.0 mg, and 9.0 mg, or placebo over 42 weeks, including a dose-escalation period of up to 16 weeks. The 5:1 randomization ratio and multinational, multicenter design reflect the operational complexity that contract manufacturers and site QA leads will need to accommodate as the program scales.

On efficacy, petrelintide delivered mean body weight reductions of up to 10.7% from baseline to week 42 versus 1.7% for placebo on the efficacy estimand; the treatment policy estimand showed reductions of up to 10.2% versus 1.4%. Cardiometabolic secondary endpoints reinforced the signal: waist circumference fell by up to 10.8 cm versus 4.3 cm with placebo, high-sensitivity C-reactive protein dropped by up to 41% versus 6%, triglycerides declined by up to 21% versus 9%, and pulse rate decreased by up to 2.9 beats per minute against a mean increase of 0.3 bpm on placebo.

The tolerability profile carries direct implications for formulation and fill-finish strategy. Gastrointestinal adverse events occurred at rates comparable to placebo; at the maximally effective dose, there were no cases of vomiting and no treatment discontinuations attributable to gastrointestinal events. For drug product teams benchmarking against the GLP-1 class, where nausea-driven discontinuation has complicated adherence modeling, petrelintide's amylin-analog mechanism appears to present a differentiated tolerability curve, one that will need to be preserved through formulation development and maintained across commercial-scale batches under 21 CFR Part 211 and applicable ICH Q10 quality system requirements.

Additional ZUPREME-1 results are being presented in an oral session at the 62nd EASD Annual Meeting on September 30, 2026, at 3:30 pm CEST, with three global Phase 3 ZUPREME registrational trials now underway for petrelintide monotherapy in chronic weight management.

The primary endpoint, percentage change in body weight from baseline to week 28, and the full secondary endpoint dataset will serve as the reference frame against which Phase 3 statistical analysis plans and manufacturing comparability protocols will be constructed.

Source: Zealand Pharma A/S via GlobeNewswire, September 29, 2026.